基于HIV-1细胞进入机制的新型疗法。 - Suppr

Suppr

超能文献

Novel therapies based on mechanisms of HIV-1 cell entry.

作者信息

Kilby J Michael, Eron Joseph J

机构信息

Department of Medicine, University of Alabama, Birmingham, USA.

出版信息

N Engl J Med. 2003 May 29;348(22):2228-38. doi: 10.1056/NEJMra022812.

DOI:10.1056/NEJMra022812

PMID:12773651

Abstract

摘要

相似文献

Novel therapies based on mechanisms of HIV-1 cell entry.

N Engl J Med. 2003 May 29;348(22):2228-38. doi: 10.1056/NEJMra022812.

HIV entry inhibitors: progress in development and application.

Yao Xue Xue Bao. 2010 Feb;45(2):131-40.

Katy, bar the door! HIV entry inhibitors.

Res Initiat Treat Action. 2000 Jun;6(2):6-12.

HIV fusion and its inhibition in antiretroviral therapy.

Rev Med Virol. 2004 Sep-Oct;14(5):321-37. doi: 10.1002/rmv.440.

Chemokine receptors as new molecular targets for antiviral therapy.

New Microbiol. 2004 Apr;27(2 Suppl 1):17-29.

HIV entry inhibitors: a new generation of antiretroviral drugs.

Acta Pharmacol Sin. 2005 Oct;26(10):1165-73. doi: 10.1111/j.1745-7254.2005.00193.x.

Progress in targeting HIV-1 entry.

Drug Discov Today. 2005 Aug 15;10(16):1085-94. doi: 10.1016/S1359-6446(05)03550-6.

[Fusion inhibitors. One year therapy with T-20--initial evaluation].

MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:42-3.

[Originality of entry inhibitors].

Med Mal Infect. 2009 Oct;39(10 Suppl 1):H1-4. doi: 10.1016/S0399-077X(09)75321-1.

HIV entry and fusion inhibitors.

Expert Opin Emerg Drugs. 2004 May;9(1):1-7. doi: 10.1517/eoed.9.1.1.32950.

引用本文的文献

Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.

Viruses. 2023 Aug 13;15(8):1732. doi: 10.3390/v15081732.

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation.

Signal Transduct Target Ther. 2021 Jul 29;6(1):288. doi: 10.1038/s41392-021-00712-2.

HIV-1 Entry and Membrane Fusion Inhibitors.

Viruses. 2021 Apr 23;13(5):735. doi: 10.3390/v13050735.

Development of Coronavirus Treatments Using Neutralizing Antibodies.

Microorganisms. 2021 Jan 13;9(1):165. doi: 10.3390/microorganisms9010165.

HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes.

Nat Chem Biol. 2020 May;16(5):529-537. doi: 10.1038/s41589-020-0496-y. Epub 2020 Mar 9.

Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.

Curr Top Med Chem. 2019;19(18):1621-1649. doi: 10.2174/1568026619666190712204603.

[Modern HIV treatment].

Internist (Berl). 2019 Apr;60(4):411-419. doi: 10.1007/s00108-019-0564-0.

Human T-Cell Development and Thymic Egress: An Infectious Disease Perspective.

For Immunopathol Dis Therap. 2015;6(1-2):33-49. doi: 10.1615/ForumImmunDisTher.2015014226.

The improved efficacy of Sifuvirtide compared with enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance.

PLoS One. 2017 Feb 16;12(2):e0171567. doi: 10.1371/journal.pone.0171567. eCollection 2017.

Synthetic Peptides as Protein Mimics.

Front Bioeng Biotechnol. 2016 Jan 19;3:211. doi: 10.3389/fbioe.2015.00211. eCollection 2015.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Novel therapies based on mechanisms of HIV-1 cell entry.

N Engl J Med. 2003 May 29;348(22):2228-38. doi: 10.1056/NEJMra022812.

HIV entry inhibitors: progress in development and application.

Yao Xue Xue Bao. 2010 Feb;45(2):131-40.

Katy, bar the door! HIV entry inhibitors.

Res Initiat Treat Action. 2000 Jun;6(2):6-12.

HIV fusion and its inhibition in antiretroviral therapy.

Rev Med Virol. 2004 Sep-Oct;14(5):321-37. doi: 10.1002/rmv.440.

Chemokine receptors as new molecular targets for antiviral therapy.

New Microbiol. 2004 Apr;27(2 Suppl 1):17-29.

HIV entry inhibitors: a new generation of antiretroviral drugs.

Acta Pharmacol Sin. 2005 Oct;26(10):1165-73. doi: 10.1111/j.1745-7254.2005.00193.x.

Progress in targeting HIV-1 entry.

Drug Discov Today. 2005 Aug 15;10(16):1085-94. doi: 10.1016/S1359-6446(05)03550-6.

[Fusion inhibitors. One year therapy with T-20--initial evaluation].

MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:42-3.

[Originality of entry inhibitors].

Med Mal Infect. 2009 Oct;39(10 Suppl 1):H1-4. doi: 10.1016/S0399-077X(09)75321-1.

HIV entry and fusion inhibitors.

Expert Opin Emerg Drugs. 2004 May;9(1):1-7. doi: 10.1517/eoed.9.1.1.32950.

引用本文的文献

Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.

Viruses. 2023 Aug 13;15(8):1732. doi: 10.3390/v15081732.

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation.

Signal Transduct Target Ther. 2021 Jul 29;6(1):288. doi: 10.1038/s41392-021-00712-2.

HIV-1 Entry and Membrane Fusion Inhibitors.

Viruses. 2021 Apr 23;13(5):735. doi: 10.3390/v13050735.

Development of Coronavirus Treatments Using Neutralizing Antibodies.

Microorganisms. 2021 Jan 13;9(1):165. doi: 10.3390/microorganisms9010165.

HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes.

Nat Chem Biol. 2020 May;16(5):529-537. doi: 10.1038/s41589-020-0496-y. Epub 2020 Mar 9.

Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.

Curr Top Med Chem. 2019;19(18):1621-1649. doi: 10.2174/1568026619666190712204603.

[Modern HIV treatment].

Internist (Berl). 2019 Apr;60(4):411-419. doi: 10.1007/s00108-019-0564-0.

Human T-Cell Development and Thymic Egress: An Infectious Disease Perspective.

For Immunopathol Dis Therap. 2015;6(1-2):33-49. doi: 10.1615/ForumImmunDisTher.2015014226.

The improved efficacy of Sifuvirtide compared with enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance.

PLoS One. 2017 Feb 16;12(2):e0171567. doi: 10.1371/journal.pone.0171567. eCollection 2017.

Synthetic Peptides as Protein Mimics.

Front Bioeng Biotechnol. 2016 Jan 19;3:211. doi: 10.3389/fbioe.2015.00211. eCollection 2015.